Summary of clinical, OCB, antibody against aquaporin-4 (AQP4-IgG) and spinal MRI characteristics* data of 26 patients with longitudinal extensive myelopathy
| Conventional multiple sclerosis (n = 13) | Non-conventional multiple sclerosis | |||
| Total (n = 13) | Neuromyelitis optica (n = 7) | Isolated longitudinal extensive myelopathy (n = 6) | ||
| Sex ratio (male/female) | 4/9 | 7/6 | 4/3 | 3/3 |
| Age at examination (years) | 44.9 (11.3) | 51.8 (12.2) | 55.9 (13.1) | 47.0 (10.3) |
| Age at onset (years) | 30.6 (8.0) | 43.6 (13.0)† | 46.0 (14.2)† | 40.2 (13.8)† |
| Disease duration (years) | 14.3 (10.0) | 8.2 (7.4) | 9.9 (9.7) | 6.3 (3.3) |
| Relapse number | 4.4 (2.5) | 2.8 (1.5) | 3.4 (1.5) | 2.2 (1.2) |
| Relapse rate | 0.6 (0.7) | 0.6 (0.5) | 0.8 (0.6) | 0.4 (0.3) |
| Final Extended Disability Status Scale | 5.1 (2.4) | 6.4 (3.6) | 8.0 (2.9)† | 5.2 (3.7) |
| Oligoclonal band in cerebrospinal fluid (+), n (%) | 3/5 (60%) | 2/10 (20%) | 0/6 (0%) | 2/4 (50%) |
| AQP4-IgG (+), n (%) | 0/10 (0%) | 1/10 (10%) | 0/4 (0%) | 1/6 (16.7%) |
| Spinal cord lesion length, segments (range) | 4.5 (1.3) (3 to 7) | 8.5 (4.5)† (3 to 18) | 7.1 (3.2) (3 to 12) | 10.2 (5.5)† (4 to 18) |
| Sagittal distribution, n (%) | ||||
| C1–C3 | 6 (46.2%) | 5 (38.5%) | 3 (42.9%) | 2 (33.3%) |
| C4–C7 | 10 (76.9%) | 7 (53.8%) | 4 (57.1%) | 3 (50.0%) |
| T1–T4 | 1 (7.7%) | 8 (61.5%)† | 4 (57.1%)† | 4 (66.7%)† |
| T5–T8 | 4 (30.8%) | 7 (53.8%) | 2 (28.6%) | 5 (83.3%) |
| T9–T12 | 0 (0%) | 3 (23.1%) | 2 (28.6%) | 1 (16.7%) |
| Axial distribution, n (%) | ||||
| Holocord‡ | 3 (23.1%) | 4 (30.8%) | 2 (28.6%) | 2 (33.3%) |
| Central cord | 6 (46.1%) | 7 (53.8%) | 3 (42.9%) | 4 (66.7%) |
| Peripheral cord | 4 (30.8%) | 2 (15.4%) | 2 (28.6%) | 0 (0%) |
| Swelling cord, n (%) | 5 (38.5%) | 10 (76.9%) | 6 (85.7%) | 4 (66.7%) |
| Gadolinium enhancement, n (%) | 2/8 (25%) | 9/12 (75.0%) | 6/7 (85.7%) | 3/5 (60%) |